MSB 7.69% $1.19 mesoblast limited

Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-69

  1. 2,121 Posts.
    lightbulb Created with Sketch. 568
    haha whatever.

    for those that think they are on the cusp of accelerated approval, I point you back to the tone and cadence of the ODAC briefs by the FDA.

    Absolute takedown...and it hasn’t aged a bit
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.